Literature DB >> 22258461

The Role of Overweight and Obesity in the Cardiorenal Syndrome.

James R Sowers, Adam Whaley-Connell, Melvin R Hayden.   

Abstract

The presence of a group of interactive maladaptive factors including hypertension, insulin resistance, metabolic dyslipidemia, obesity, microalbuminuria, and/or reduced renal function constitute the cardiorenal metabolic syndrome (CRS). Overweight, obesity, and chronic kidney disease (CKD) have grown to pandemic proportions in industrialized countries during the past decade. The fact that these interactive factors promote heart and renal disease has been documented in large population-based studies. Obesity seems to be the driving force behind the development of heart disease and CKD and therefore the CRS. The relationship between overweight/obesity and kidney disease begins in early childhood and appears to be related to overconsumption of high-fructose corn syrup and insufficient physical activity. Today, 13 million children are obese, and over 70% of these children are likely to become obese adults. Indeed, approximately 30% of male and 34% of female adults in the United States are obese. This lifestyle-related epidemic will be a major societal medical and economic problem that will accentuate the current epidemic of CKD in the United States and other industrialized and emerging industrialized countries. In this article, we will review the potential mechanisms by which obesity and other metabolic abnormalities interact to promote heart and progressive kidney disease.
© 2011 S. Karger AG, Basel.

Entities:  

Keywords:  Adiposity; Cardiorenal metabolic syndrome; Chronic kidney disease; Heart failure; Metabolic dyslipidemia; Obesity

Year:  2011        PMID: 22258461      PMCID: PMC3101516          DOI: 10.1159/000322822

Source DB:  PubMed          Journal:  Cardiorenal Med        ISSN: 1664-5502            Impact factor:   2.041


  69 in total

1.  Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population.

Authors:  Grégoire Wuerzner; Menno Pruijm; Marc Maillard; Pascal Bovet; Claude Renaud; Michel Burnier; Murielle Bochud
Journal:  Am J Kidney Dis       Date:  2010-06-09       Impact factor: 8.860

2.  Reversible obesity-related glomerulopathy following weight reduction.

Authors:  Huy A Tran
Journal:  Med J Aust       Date:  2006-04-03       Impact factor: 7.738

3.  Prevalence of overweight and obesity in the United States, 1999-2004.

Authors:  Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal
Journal:  JAMA       Date:  2006-04-05       Impact factor: 56.272

Review 4.  Cardiac hypertrophy, substrate utilization and metabolic remodelling: cause or effect?

Authors:  Rebecca H Ritchie; Lea M D Delbridge
Journal:  Clin Exp Pharmacol Physiol       Date:  2006 Jan-Feb       Impact factor: 2.557

5.  Cardiomyocyte-restricted overexpression of endothelial nitric oxide synthase (NOS3) attenuates beta-adrenergic stimulation and reinforces vagal inhibition of cardiac contraction.

Authors:  Paul B Massion; Chantal Dessy; Fanny Desjardins; Michel Pelat; Xavier Havaux; Catharina Belge; Pierre Moulin; Yves Guiot; Olivier Feron; Stefan Janssens; Jean-Luc Balligand
Journal:  Circulation       Date:  2004-10-18       Impact factor: 29.690

6.  Body mass index and the risk of development of end-stage renal disease in a screened cohort.

Authors:  Kunitoshi Iseki; Yoshiharu Ikemiya; Kozen Kinjo; Taku Inoue; Chiho Iseki; Shuichi Takishita
Journal:  Kidney Int       Date:  2004-05       Impact factor: 10.612

Review 7.  Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.

Authors:  Richard J Johnson; Mark S Segal; Yuri Sautin; Takahiko Nakagawa; Daniel I Feig; Duk-Hee Kang; Michael S Gersch; Steven Benner; Laura G Sánchez-Lozada
Journal:  Am J Clin Nutr       Date:  2007-10       Impact factor: 7.045

8.  The effects of weight loss on renal function in patients with severe obesity.

Authors:  Avry Chagnac; Tali Weinstein; Michal Herman; Judith Hirsh; Uzi Gafter; Yaacov Ori
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

9.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study.

Authors:  M S Lauer; K M Anderson; W B Kannel; D Levy
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

10.  National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events.

Authors:  George Bakris; Joseph Vassalotti; Eberhard Ritz; Christoph Wanner; George Stergiou; Mark Molitch; Richard Nesto; George A Kaysen; James R Sowers
Journal:  Kidney Int       Date:  2010-08-18       Impact factor: 10.612

View more
  53 in total

Review 1.  Basic science: Pathophysiology: the cardiorenal metabolic syndrome.

Authors:  Adam Whaley-Connell; James R Sowers
Journal:  J Am Soc Hypertens       Date:  2014-07-05

2.  Pigmented rice bran and plant sterol combination reduces serum lipids in overweight and obese adults.

Authors:  Nobuko Hongu; David D Kitts; Jerzy Zawistowski; Cynthia M Dossett; Aneta Kopeć; Benjamin T Pope; Maciej S Buchowski
Journal:  J Am Coll Nutr       Date:  2014       Impact factor: 3.169

3.  Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats.

Authors:  Annayya R Aroor; James R Sowers; Shawn B Bender; Ravi Nistala; Mona Garro; Irina Mugerfeld; Melvin R Hayden; Megan S Johnson; Muhammad Salam; Adam Whaley-Connell; Vincent G Demarco
Journal:  Endocrinology       Date:  2013-05-07       Impact factor: 4.736

Review 4.  Obesity and heart failure as a mediator of the cerebrorenal interaction.

Authors:  Ankur Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

5.  Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy.

Authors:  Keith C Ferdinand
Journal:  Cardiorenal Med       Date:  2012-10-26       Impact factor: 2.041

6.  Metformin in peritoneal dialysis: a pilot experience.

Authors:  Abdulla Khalaf Al-Hwiesh; Ibrahiem Saeed Abdul-Rahman; Mohammad Ahmad Nasr El-Deen; Emmanuel Larbi; Jose C Divino-Filho; Fahd Abdul-Aziz Al-Mohanna; Krishan L Gupta
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 7.  Type 2 diabetes mellitus and hypertension: an update.

Authors:  Guido Lastra; Sofia Syed; L Romayne Kurukulasuriya; Camila Manrique; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

8.  Phosphoprotein Phosphatase PP2A Regulation of Insulin Receptor Substrate 1 and Insulin Metabolic Signaling.

Authors:  Chirag Mandavia; James R Sowers
Journal:  Cardiorenal Med       Date:  2012-11-16       Impact factor: 2.041

Review 9.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

10.  Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.

Authors:  Brian Bostick; Javad Habibi; Lixin Ma; Annayya Aroor; Nathan Rehmer; Melvin R Hayden; James R Sowers
Journal:  Metabolism       Date:  2014-04-12       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.